Talphera Inc.
Suletud
0.8
Ülevaade
Aktsiahinna muutus
24h
Min
0.78
Max
0.84
Sissetulek | 1.2M -2.6M |
|---|---|
Kasumimarginaal | -443,600 |
Töötajad | 12 |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +268.24% upside |
Järgmine tulemuste avaldamine | 13. aug 2026 |
|---|
Turukapital | -519K 34M |
|---|---|
Eelmine avamishind | 0.8 |
Eelmine sulgemishind | 0.8 |
Talphera Inc. Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Talphera Inc. Prognoos
Hinnasiht
By TipRanks
268.24% tõus
12 kuu keskmine prognoos
Keskmine 3.13 USD 268.24%
Kõrge 3.5 USD
Madal 3 USD
Põhineb 4 Wall Streeti analüütiku instrumendi Talphera Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Maksueelne kasum
Müük
Intressikulud võla pealt
Ärikasum
$
Ettevõttest Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
